Microencapsulation of a synthetic peptide epitope for HTLV-1 in biodegradable poly(D,L-lactide-co-glycolide) microspheres using a novel encapsulation technique

Journal of Microencapsulation

Volumn 18, Issue 5, 2001, Pages 663-677

  Frangione Beebe, M ^a   Rose, R T ^a   Kaumaya, P T P ^a   Schwendeman, S P ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Biodegradable microspheres; HTLV 1; Peptide vaccines; Poly (D,L lactide co glycolide)

Indexed keywords

BOVINE SERUM ALBUMIN; CANCER VACCINE; COTTON SEED OIL; EPITOPE; FLUORESCEIN ISOTHIOCYANATE; GLUTAMINE DERIVATIVE; MICROSPHERE; MINERAL OIL; MVFMF2; N ACETYL GLUCOSAMINE 3YL ACETYL LEVO ALANYL DEXTRO ISOGLUTAMINE; POLYGLACTIN; SORBITAN TRIOLEATE; SYNTHETIC PEPTIDE; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; BIODEGRADATION; CANCER IMMUNIZATION; CONTROLLED STUDY; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; IN VIVO STUDY; INOCULATION; MICROENCAPSULATION; NONHUMAN; RABBIT; T CELL LEUKEMIA;

ANIMALS; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; LACTIC ACID; MICROSPHERES; PEPTIDE FRAGMENTS; POLYGLYCOLIC ACID; POLYMERS; RABBITS; SERUM ALBUMIN, BOVINE; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 0035217761     PISSN: 02652048     EISSN: None     Source Type: Journal    
DOI: 10.1080/02652040110055216     Document Type: Article

References (39)

1. Controlled-release vaccines-biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles
2. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems
3. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine
4. Modulation of rifampicin release from spray-dried microspheres using combinations of poly-(DL-lactide)
5. New approaches for encapsulation of peptides into poly(lactic/glycolic acid) microspheres
6. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres
7. Controlled vaccine release in the gut-associated lymphoid tissues. 1. Orally administered biodegradable microspheres target the Peyer-s patches
8. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response
9. Biodegradable, microspheres as a vaccine delivery system
10. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies
11. Poly(DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines
12. Identification of two promiscuous T cell epitopes from tetanus toxin
13. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity
14. Engineered topographic determinants with alpha beta, beta alpha beta, and beta alpha beta alpha topologies show high affinity binding to native protein antigen (lactate dehydrogenase-C4)
15. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction
16. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity
17. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid
18. Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: Influence of molecular weight and copolymer ratio of polymer
19. Controlled release microparticles for vaccine development
20. Biodegradable microparticles for oral immunization
21. Biodegradable microparticles as controlled release antigen delivery systems
22. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46
23. University immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells
24. Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans
25. Effect of formulation variables on in vitro drug release and micromeritic properties of modified release ibuprofen microspheres
26. Among all human T-cell leukemia virus type 1 proteins, tax, polymerase, and envelope proteins are predicted as preferential targets for the HLA-A2-restricted cytotoxic T-cell response
27. Physical aging of progesterone-loaded poly(D,L,-lactide-co-glycolide) microspheres
28. Murine MHC polymorphism and T cell specificities
29. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation
30. Stability of proteins and their delivery from biodegradable polymer microspheres
31. Progress and challenges for peptide, protein, and vaccine delivery from implantable polymeric systems
32. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins
33. Controlled delivery of diphtheria toxoid using biodegradable poly(D,L-lactide) microcapsules
34. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules
35. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer
36. Particle size studies for subcitaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulations
37. Modification of release rates of cyclosporin A from polyl(L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres
38. Mechanisms of solvent evaporation encapsulation processes: Prediction of solvent evaporation rate
39. Stabilization of proteins encapsulated in injectable poly(lactide-co-glycolide)